REGNRegeneron PharmaceuticalsRunning, no new patients
A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies
B-cell Non-Hodgkin Lymphoma (B-NHL)
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 2
- Patients
- 515 (final count)
- Started
- Nov 13, 2019
- Main results expected
- Jun 17, 2026
- Fully finished
- Dec 15, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response Rate (ORR), as assessed by independent central review
Measured over: Up to 52 weeks of study treatment
ORR, as assessed by independent central review
Measured over: Up to 36 weeks of study treatment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03888105 · record last updated 2026-07-31 · checked 2026-11-09 15:47 UTC